Free Trial
NASDAQ:AVDL

Avadel Pharmaceuticals Q1 2025 Earnings Report

Avadel Pharmaceuticals logo
$8.03 -0.12 (-1.47%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$8.16 +0.13 (+1.67%)
As of 04/17/2025 04:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Avadel Pharmaceuticals EPS Results

Actual EPS
N/A
Consensus EPS
-$0.06
Beat/Miss
N/A
One Year Ago EPS
N/A

Avadel Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
$50.57 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Avadel Pharmaceuticals Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Wednesday, May 7, 2025
Conference Call Time
8:30AM ET

Conference Call Resources

Avadel Pharmaceuticals Earnings Headlines

Avadel, nference announce publication of data on sodium oxybate
Real Americans Don’t Wait on Wall Street’s Next Move
What's happening in the markets right now should concern every freedom-loving American who's worked hard and saved smart. Your 401(k) doesn't deserve to be dragged through the mud by tariffs, trade wars, reckless spending, and political standoffs. And you don't have to stand by while Wall Street plays roulette with your future.
Q1 Earnings Forecast for AVDL Issued By Leerink Partnrs
Q2 Earnings Estimate for AVDL Issued By Leerink Partnrs
See More Avadel Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Avadel Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Avadel Pharmaceuticals and other key companies, straight to your email.

About Avadel Pharmaceuticals

Avadel Pharmaceuticals (NASDAQ:AVDL) operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

View Avadel Pharmaceuticals Profile

More Earnings Resources from MarketBeat